Illumina Faces EU Interim Measures Over Grail Deal

US life sciences company Illumina faces interim measures for closing its US$8 billion cash-and-stock takeover of cancer detection test maker Grail before gaining approval for the deal, EU antitrust regulators announced on Monday, September 20.

Illumina closed the Grail takeover last month and stated it would hold the company separate while waiting for a European Commission decision on the deal, defying EU merger rules against gun-jumping. 

Previous instances of gun-jumping have resulted in companies being hit with million-euro fines. Sanctions can be as much as 10% of a company’s global turnover.

The EU competition enforcer stated it had sent a statement of objections to the companies, setting out the interim measures it plans to take. It did not provide details.

Under EU merger rules, the competition watchdog can order companies to unwind their deals or sell off shares or assets acquired for violations.

Commission Vice-President Margrethe Vestager underlined the seriousness of Illumina’s actions, saying it was the first time companies had openly implemented a deal while regulators were still investigating.

“The standstill obligation is a cornerstone of our ex-ante merger control regime which aims at preventing harmful effects to competition while our review is ongoing,” she said in a statement.

Read More: Illumina Closes $8B Grail Merger Despite EU Probe

The Commission stated the interim measures aim to restore and maintain effective competition pending a final decision on the deal.

“The envisaged interim measures take note of Illumina’s own unilateral proposal to hold Grail separate, but go beyond Illumina’s proposal in addressing a number of serious shortcomings identified in that proposal,” it stated.

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.